In the award citation Frost and Sullivan focused on the innovative nature of the technology and the use of advanced Tissue Characterisation algorithms to visualise the position and extent of tissue suspected of being malignant in the prostate gland. Frost and Sullivan states that the adoption of Prostate HistoScanning™ is poised to lead to a significant change in biopsy practice with urologists being able to select patients for biopsy and to direct biopsies to those areas of the gland that are likely to contain the malignant tissue.

 

Full details of the award and why HistoScanning™ was selected can be found in the 2011 Frost and Sullivan European Medical Diagnostics and Imaging, Technology Innovation Award report, its press release and the hall-of-fame.